The incidence of infants with TsB ≥450 μmol/L was 45/100,000/year. Infants with a TsB ≥600 μmol/L had a substantial risk of developing acute advanced and chronic bilirubin encephalopathy, and the incidence of these conditions was 0.6 per 100,000.

By using light-emitting diodes, we found a linear relation between light irradiance in the range of 20 to 55 μW/cm(2)/nm and a decrease in TsB after 24 hours of therapy, with no evidence of a saturation point.

Using the parent-completed ASQ, we found no evidence of developmental delay in children aged between 1 and 5 years with severe neonatal hyperbilirubinemia compared with a matched control group.

No abstract

No abstract

No evidence was found of an increased risk of deficits in motor development, executive function, or hearing in children with extreme hyperbilirubinaemia who did not have intermediate or advanced bilirubin encephalopathy.

No abstract

TcB determined with JM-103 gave values much lower than those obtained with BiliCheck. The underestimation of TsB increased with increasing concentrations. By using transcutaneous bilirubinometers in preterm neonates, 24-36% of the blood samples could be saved.